The text starts here.

News Release

June 28, 2004

Eisai Launches New Formulation of ARICEPT (R),
Rapid Disintegration Tablet, in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced the July 1st launch of ARICEPT (R) D Tablets 3mg and ARICEPT (R) D Tablets 5mg, rapid disintegration (RPD) tablets, as a new formulation of the Alzheimer's disease treatment, ARICEPT (R) (donepezil hydrochloride), following the completion of the national health insurance price listing on June 25, 2004.

ARICEPT (R) is the first treatment for Alzheimer's disease in the world that offers the option of a RPD tablet formulation. The new form, which rapidly disintegrates in the mouth, is designed to make administration easier for patients who experience difficulty or discomfort in swallowing tablets. Eisai hopes that these new formulations will contribute to improved compliance for patients suffering from Alzheimer's disease. Eisai filed applications for the RPD tablet formulation of ARICEPT (R) with regulatory agencies in the U.S. and EU in December 2003.

ARICEPT (R), an acetylcholinesterase inhibitor synthesized by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter in the brain. ARICEPT (R) currently is indicated for the treatment of mild to moderate Alzheimer's disease and is marketed in 76 countries worldwide. Eisai markets ARICEPT (R) through co-promotion with Pfizer in Japan, the United States, the United Kingdom, Germany, France and Spain, and markets solely in Asian countries.

[The product outline and a photograph are attached below for reference]


Eisai Co., Ltd.
Corporate Communications Department
03-3817-5120 (Tokyo)

[ Product Outline of ARICEPT (R) D Tablets 3mg, ARICEPT (R) D Tablets 5mg ]

Product Name : ARICEPT (R) D Tablets 3mg, ARICEPT (R) D Tablets 5mg
Generic Name : donepezil hydrochloride
Composition : ARICEPT (R) D Tablets 3mg: each yellow RPD tablet contains 3mg of donepezil hydrochloride
ARICEPT (R) D Tablets 5mg: each white RPD tablet contains 5mg of donepezil hydrochloride
Indication : Inhibition of the progress of the symptoms of dementia in mild to moderate dementia of the Alzheimer's type
Dosage and Administration : The usual initial adult dose for oral use is 3mg of donepezil hydrochloride once daily. After 1 to 2 weeks the dosage is increased to 5mg.
Price : ARICEPT (R) D Tablets 3mg: 318.80 yen
ARICEPT (R) D Tablets 5mg: 482.40 yen
Package : ARICEPT (R) D Tablets 3mg: 28 tablets (PTP14T 2)
140 tablets (PTP14T 10)
ARICEPT (R) D Tablets 5mg: 56 tablets (PTP14T 4)
140 tablets (PTP14T 10)
Production Approval Date : February 26, 2004
Listed Date in the National Health Insurance List in Japan : June 25, 2004
Projected Launch Date : July 1, 2004
Manufacturer and Distributor : Eisai Co., Ltd.
Co-Distributor : Pfizer Pharmaceuticals Inc.

[ Product photograph ]

ARICEPT(R) D Tablets

[ Other ARICEPT (R) Products ]

Product Name Formulation Price
ARICEPT (R) Tablets 3mg film-coated tablet 318.80 yen/tablet
ARICEPT (R) Tablets 5mg film-coated tablet 482.40 yen/tablet
ARICEPT (R) Fine granules 0.5% fine granules 449.80 yen/g